Management of Elevated Creatinine Levels

Initial Assessment and Management

The American Society of Clinical Oncology recommends verifying elevated creatinine with repeat testing and determining if the elevation is acute or chronic by comparing with previous values 1
Evaluate for potential causes including medications, dehydration, urinary tract infection, and other conditions, as suggested by the Journal of Clinical Oncology 1, 2
The American Diabetes Association recommends discontinuing any potentially nephrotoxic medications and avoiding nonsteroidal anti-inflammatory drugs 3
Assess for concomitant conditions that may contribute to kidney dysfunction, including hypertension and diabetes, as recommended by the American Society of Nephrology and the American Diabetes Association 3, 4

The American Society of Nephrology recommends aggressive blood pressure control for patients with hypertension and elevated creatinine, with a target blood pressure of <130/80 mmHg 4
The American Heart Association suggests that ACE inhibitors or angiotensin receptor blockers (ARBs) should be first-line therapy for patients with hypertension and elevated creatinine, especially those with proteinuria 4
For patients with type 2 diabetes and nephropathy, regular monitoring of urine albumin-to-creatinine ratio is recommended to assess treatment response, as suggested by the American Diabetes Association 3
Optimize glycemic control to prevent further kidney damage, as recommended by the American Diabetes Association 3

AKI is diagnosed by a 50% or greater sustained increase in serum creatinine over a short period, as defined by the American Diabetes Association 3
Management includes ensuring adequate hydration, discontinuing nephrotoxic medications, treating underlying infections if present, and careful fluid resuscitation in cases of volume depletion, as recommended by the American Gastroenterological Association and the American Diabetes Association 3, 5

Monitor creatinine levels weekly in acute situations and regularly in chronic conditions, as suggested by the Journal of Clinical Oncology 2
For patients with chronic kidney disease, monitor both albuminuria and eGFR annually, as recommended by the American Diabetes Association 3
Monitor serum potassium in patients treated with ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists, especially with eGFR <60 mL/min/1.73 m², as suggested by the American Diabetes Association 3

Small elevations in serum creatinine (up to 30% from baseline) with RAS blockers should not be confused with AKI and are not a reason to discontinue therapy, as recommended by the American Diabetes Association 3
Kidney biopsy is generally not necessary unless the kidney injury is refractory to standard treatments, as suggested by the Journal of Clinical Oncology 1
Patients with elevated creatinine should be referred to nephrology if there is uncertainty about etiology, worsening proteinuria, or decreasing eGFR, as recommended by the American Diabetes Association 6